Skip to main content
Top
Published in: Diabetology International 3/2013

01-09-2013 | Original Article

Long-term miglitol administration suppresses postprandial glucose-dependent insulinotropic polypeptide secretion

Authors: Keisuke Sumi, Tsuyoshi Ohkura, Naoya Yamamoto, Youhei Fujioka, Kazuhiko Matsuzawa, Shoichiro Izawa, Hideki Shiochi, Hiroshi Kinoshita, Hiroko Ohkura, Masahiko Kato, Kazuhiro Yamamoto, Shin-ichi Taniguchi

Published in: Diabetology International | Issue 3/2013

Login to get access

Abstract

Aims

Several studies indicated that short-term administration of α-glucosidase inhibitors (α-GIs) significantly reduces postprandial glucose-dependent insulinotropic polypeptide (GIP) secretion. However, little is known about the long-term effect. We investigated the effects of long-term miglitol administration on GIP secretion and body weight in patients with type 2 diabetes.

Methods

This study included ten patients with type 2 diabetes administered 150 mg miglitol and another ten patients treated with glinide. We evaluated postprandial GIP, plasma glucose, insulin and triglyceride levels at baseline and after 12 months of each administration.

Results

After 12 months, postprandial glucose levels significantly decreased in each group. Miglitol significantly suppressed postprandial plasma insulin levels at 30 min compared to glinide (97.9 vs. 257.3 pmol/l; P < 0.01). The fasting GIP level in the glinide group after 12 months significantly increased compared to before administration (15.5 vs. 24.5 pg/ml), but miglitol did not affect the fasting GIP level. Miglitol significantly reduced postprandial GIP levels at 30, 60 and 120 min (28.8, 45.3 and 42.4 vs. 137.4, 130.8 and 108.7 pg/ml; P < 0.01, P < 0.05, P < 0.01) and the delta area under the curve of GIP (12M−0M) (−70.8 vs. 57.2 pg min/ml; P < 0.05) compared to glinide. Miglitol significantly decreased postprandial triglyceride levels, but glinide did not. Miglitol slightly reduced body weight (−0.6 kg) and waist circumference (−1.0 cm); however, glinide slightly increase body weight (+0.4 kg) and waist circumference (+0.6 cm).

Conclusions

We conclude long-term miglitol administration suppressed postprandial GIP secretion, in association with improvements in body weight, postprandial blood glucose, insulin and triglyceride levels.
Literature
1.
go back to reference Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.PubMedCrossRef Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.PubMedCrossRef
2.
go back to reference Narita T, Katsuura Y, Sato T. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med. 2009;26:187–8.PubMedCrossRef Narita T, Katsuura Y, Sato T. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med. 2009;26:187–8.PubMedCrossRef
3.
go back to reference Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4:329–35.PubMedCrossRef Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4:329–35.PubMedCrossRef
4.
go back to reference Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes. 2006;55:86–91.CrossRef Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes. 2006;55:86–91.CrossRef
5.
go back to reference Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia. 2007;50:1752–62.PubMedCrossRef Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia. 2007;50:1752–62.PubMedCrossRef
6.
go back to reference Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91(3):457–65.PubMedCrossRef Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91(3):457–65.PubMedCrossRef
7.
go back to reference Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59:521–49.PubMedCrossRef Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59:521–49.PubMedCrossRef
8.
go back to reference Tsujino D, Nishimura R, Taki K, Morimoto A, Tajima N, Utsunomiya K. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study—the MAJOR study. Diabetes Technol Ther. 2011;13(3):303–8.PubMedCrossRef Tsujino D, Nishimura R, Taki K, Morimoto A, Tajima N, Utsunomiya K. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study—the MAJOR study. Diabetes Technol Ther. 2011;13(3):303–8.PubMedCrossRef
9.
go back to reference Emoto T, Sawada T, Yokoyama M. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2012;109(1):42–6.PubMedCrossRef Emoto T, Sawada T, Yokoyama M. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2012;109(1):42–6.PubMedCrossRef
10.
go back to reference Segal P, Feig PU, Schernthaner G. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care. 1997;20:687–91.PubMedCrossRef Segal P, Feig PU, Schernthaner G. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care. 1997;20:687–91.PubMedCrossRef
11.
go back to reference Yoshino G. The test meal A:A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jpn Diabetes Soc. 2006;49:361–71. Yoshino G. The test meal A:A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jpn Diabetes Soc. 2006;49:361–71.
12.
go back to reference The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010;53:450–67. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010;53:450–67.
13.
go back to reference Somogyi M. Insulin as a cause of extreme hyperglycemia and instability. Week Bull St Louis Med Soc. 1938;32:498–510. Somogyi M. Insulin as a cause of extreme hyperglycemia and instability. Week Bull St Louis Med Soc. 1938;32:498–510.
14.
go back to reference Arakawa M. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism. 2008;57:1299–306.PubMedCrossRef Arakawa M. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism. 2008;57:1299–306.PubMedCrossRef
15.
go back to reference Hücking K, Kostic Z, Pox C. α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7–36 amide) and to delay gastric emptying in type 2 diabetic patients. Diabet Med. 2005;22:470–6.PubMedCrossRef Hücking K, Kostic Z, Pox C. α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7–36 amide) and to delay gastric emptying in type 2 diabetic patients. Diabet Med. 2005;22:470–6.PubMedCrossRef
16.
go back to reference DeLeon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101–6.PubMedCrossRef DeLeon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101–6.PubMedCrossRef
17.
go back to reference Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12.PubMedCrossRef Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12.PubMedCrossRef
18.
go back to reference Kawamori R. Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Res Clin Pract. 1998;40:S35–42.PubMedCrossRef Kawamori R. Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Res Clin Pract. 1998;40:S35–42.PubMedCrossRef
19.
go back to reference Hiki M, Shimada K. Single administration of α-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease. Circ J. 2010;74:1471–8.PubMedCrossRef Hiki M, Shimada K. Single administration of α-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease. Circ J. 2010;74:1471–8.PubMedCrossRef
20.
go back to reference Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism. 1996;45:731–7.PubMedCrossRef Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism. 1996;45:731–7.PubMedCrossRef
21.
go back to reference Ebert R, Creutzfeldt W. Decreased GIP secretion through impairment of absorption. Front Horm Res. 1980;7:192–210. Ebert R, Creutzfeldt W. Decreased GIP secretion through impairment of absorption. Front Horm Res. 1980;7:192–210.
22.
go back to reference Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol. 2001;88:09–15.CrossRef Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol. 2001;88:09–15.CrossRef
23.
go back to reference Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab. 2004;6:384–90.PubMedCrossRef Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab. 2004;6:384–90.PubMedCrossRef
24.
go back to reference Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab. 2012;14(3):283–7.PubMedCrossRef Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab. 2012;14(3):283–7.PubMedCrossRef
Metadata
Title
Long-term miglitol administration suppresses postprandial glucose-dependent insulinotropic polypeptide secretion
Authors
Keisuke Sumi
Tsuyoshi Ohkura
Naoya Yamamoto
Youhei Fujioka
Kazuhiko Matsuzawa
Shoichiro Izawa
Hideki Shiochi
Hiroshi Kinoshita
Hiroko Ohkura
Masahiko Kato
Kazuhiro Yamamoto
Shin-ichi Taniguchi
Publication date
01-09-2013
Publisher
Springer Japan
Published in
Diabetology International / Issue 3/2013
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-013-0116-0

Other articles of this Issue 3/2013

Diabetology International 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.